These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12644732)

  • 21. Flupenthixol decanoate and injection site abscesses in an obese patient.
    Andrade C
    Aust N Z J Psychiatry; 2002 Aug; 36(4):561-2. PubMed ID: 12169162
    [No Abstract]   [Full Text] [Related]  

  • 22. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.
    Petrakis IL; O'Malley S; Rounsaville B; Poling J; McHugh-Strong C; Krystal JH;
    Psychopharmacology (Berl); 2004 Mar; 172(3):291-7. PubMed ID: 14634716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
    Mohamed S; Rosenheck RA; Lin H; Swartz M; McEvoy J; Stroup S
    J Nerv Ment Dis; 2015 Jul; 203(7):486-92. PubMed ID: 26075840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients.
    Whatley SA; Curti D; Das Gupta F; Ferrier IN; Jones S; Taylor C; Marchbanks RM
    Mol Psychiatry; 1998 May; 3(3):227-37. PubMed ID: 9672898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating substance abuse in schizophrenia. An initial report.
    Bennett ME; Bellack AS; Gearon JS
    J Subst Abuse Treat; 2001 Mar; 20(2):163-75. PubMed ID: 11306219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Non-compliance and lack of indications for depot treatment as reasons for exclusion from adequate prevention of recurrence].
    Jakobitsch A; Haug HJ; Greger J; Osterheide M; Pach J; Sprenger R; Tegeler J; Budde G
    Psychiatr Prax; 1996 Sep; 23(5):236-9. PubMed ID: 8992517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comorbidity of schizophrenia and substance abuse: implications for treatment.
    Mueser KT; Bellack AS; Blanchard JJ
    J Consult Clin Psychol; 1992 Dec; 60(6):845-56. PubMed ID: 1460148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of self-help group attendance on relapse rates after alcohol detoxification in a controlled study.
    Mueller SE; Petitjean S; Boening J; Wiesbeck GA
    Alcohol Alcohol; 2007; 42(2):108-12. PubMed ID: 17255151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive behavior therapy for schizophrenia in patients with mild to moderate substance misuse problems.
    Naeem F; Kingdon D; Turkington D
    Cogn Behav Ther; 2005; 34(4):207-15. PubMed ID: 16498749
    [No Abstract]   [Full Text] [Related]  

  • 31. [Impact of alcohol dependence on the course and psychopathology of schizophrenia].
    Konarzewska B; Popławska R; Galińska B; Szulc A; Markowski T
    Psychiatr Pol; 2007; 41(5):715-26. PubMed ID: 18421926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional striatal volume abnormalities in schizophrenia: effects of comorbidity for alcoholism, recency of alcoholic drinking, and antipsychotic medication type.
    Deshmukh A; Rosenbloom MJ; De Rosa E; Sullivan EV; Pfefferbaum A
    Schizophr Res; 2005 Nov; 79(2-3):189-200. PubMed ID: 15963693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism.
    Kampman KM; Pettinati HM; Lynch KG; Whittingham T; Macfadden W; Dackis C; Tirado C; Oslin DW; Sparkman T; O'Brien CP
    J Clin Psychopharmacol; 2007 Aug; 27(4):344-51. PubMed ID: 17632217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia.
    Petrakis IL; Leslie D; Finney JW; Rosenheck R
    Am J Addict; 2006; 15(1):44-9. PubMed ID: 16449092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid].
    Pach J; Finkbeiner T; Glaser T; Haug J; Osterheider M; Tegeler J
    Fortschr Neurol Psychiatr; 1998 Oct; 66(10):442-9. PubMed ID: 9825249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term course of substance use disorders among patients with severe mental illness.
    Bartels SJ; Drake RE; Wallach MA
    Psychiatr Serv; 1995 Mar; 46(3):248-51. PubMed ID: 7796211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study on schizophrenic patients with dual diagnosis.
    Modestin J; Gladen CJ; Christen S
    J Addict Dis; 2001; 20(4):41-51. PubMed ID: 11760925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novelty-seeking among schizophrenia patients with comorbid alcohol abuse.
    Kim JH; Kim D; Park SH; Lee HB; Chung EK
    J Nerv Ment Dis; 2007 Jul; 195(7):622-4. PubMed ID: 17632255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients.
    Hertling I; Philipp M; Dvorak A; Glaser T; Mast O; Beneke M; Ramskogler K; Saletu-Zyhlarz G; Walter H; Lesch OM
    Neuropsychobiology; 2003; 47(1):37-46. PubMed ID: 12606844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability of low dose neuroleptics: a case control study of flupenthixol.
    Fritze J; Spreda I
    Eur Neuropsychopharmacol; 1997 Nov; 7(4):261-6. PubMed ID: 9443657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.